A pilot survey of attitudes and knowledge about opioid substitution therapy for HTV-infected prisoners

Journal of Opioid Management

Volumn 4, Issue 2, 2008, Pages 81-86

  Springer, Sandra A ^a   Bruce, Robert D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Buprenorpbine; Criminal justice system; HIV; Incarceration; Methadone; Opioids; Prison; Prisoners

Indexed keywords

ANTIRETROVIRUS AGENT; BUPRENORPHINE; METHADONE; OPIATE;

ARTICLE; CASE MANAGEMENT; CONTROLLED STUDY; DETOXIFICATION; DRUG MISUSE; HEALTH PERSONNEL ATTITUDE; HEALTH PROMOTION; HEALTH SURVEY; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; MORTALITY; OPIATE ADDICTION; PATIENT COMPLIANCE; PATIENT REFERRAL; PILOT STUDY; PREGNANCY; PRISON; PRISONER; RECIDIVISM; RELAPSE; SUBSTITUTION THERAPY; UNITED STATES;

EID: 45249109774     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2008.0012     Document Type: Article

References (30)

1. Beck A, Karber J, Harrison P: Prison and jail inmates at midyear 2001. Bureau of Justice Statistics Bulletin. 2002; NCJ 191702. Available at http://www.ojp.usdoj.gov/bjs/pub/pdf/pjim01.pdf.
2. Hammett TM, Harmon MP, Rhodes W: The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health. 2002; 92: 1789-1794.
3. Springer SA, Pesanti E, Hodges J, et al.: Effectiveness of antiretroviral therapy among HIV-infected prisoners: Reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis. 15 2004; 38: 1754-1760.
4. Rich JD, Boutwell AE, Shield DC, et al.: Attitudes and practices regarding the use of methadone in US state and federal prisons. J Urban Health. 2005; 82: 411-419.
5. Andrews S, Sorensen J, Guydish J, et al.: Knowledge and attitudes about methadone maintenance among STaff working in a therapeutic community. J Mainten Addict. 2005; 3: 47-59.
6. Altice F, Khoshnood K: Transitional Case Management as a strategy for Linking HIV-Infected Prisoners to Community Health and Social Services (Project TLC). Connecticut Department of Public Health Monograph, 1997.
7. Dolan K, Hall W, Wodak A: Methadone maintenance reduces injecting in prison. BMJ. 1996; 312(7039):1162.
8. Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four-year follow-up of imprisoned male heroin users and methadone treatment: Mortality, re-incarceration and hepatitis C infection. Addiction. 2005; 100: 820-828.
9. Smith-Rohrberg D, Bruce RD, Altice FL: Review of corrections-based therapy for opiate-depenndent patients: Implications for buprenorphine treatment among correctional populations. J Drug Issues. 2004; 34: 451-480.
10. WHO: World Health Organization Guidelines on HIV Infection and AIDS in Prison. Strasbourg: Council of Europe, Ministers of the State Members, 1993.
11. World Health Organization UNOODaC, and the Joint United Nations Programme on HIV/AIDS: Joint Position Paper on Substitution Maintenance Therapy in the Management of Opioid Dependence and HIV/AIDS Prevention. Geneva: WHO, 2004.
12. Levasseur L, Marzo J, Ross N, et al: Frequency of re-incarcerations in the same detention center: Role of stubstituion therapy. A preliminary retrospective analysis. Ann Med Intern. 2002; 153(3 suppl): 1S14-1S19.
13. Durand E: [Changes in high-dose buprenorphine maintenance therapy at the Fleury-Merogis (France) prison since 1996]. Ann Med Interne (Paris). 2001; 152(suppl 7): 9-14.
14. Springer SA, Altice FL: Managing HIV/AIDS in correctional settings. Curr HIV/AIDS Rep. 2005; 2: 165-170.
15. Mumola C: Substance abuse and treatment, state and federal prisoners, 1997. Bureau of Justice Statistics Report. Jan 1999; NCJ 172871. Available at http://www.ojp.usdoj.gov/bjs/pub/pdf/satsfp97.pdf.
16. Fallon B: The Key Extended Entry Program (KEEP): From the community side of the bridge. Mt Sinai J Med. 2001; 68: 21-27.
17. Sibbald B: Methadone maintenance expands inside federal prisons. CMAJ. 2002; 167: 1154.
18. Tomasino V, Swanson AJ, Nolan J, et al.: The Key Extended Entry Program (KEEP): A methadone treatment program for opiate-dependent inmates. Mt Sinai J Med. 2001; 68: 14-20.
19. Byrne A, Dolan K: Methadone treatment is widely accepted in prisons in New South Wales. BMJ. 1998; 316: 1744-1745.
20. Kinlock TW, Battjes RJ, Schwartz RP: A novel opioid maintenance program for prisoners: Preliminary findings. J Subst Abuse Treat. 2002; 22: 141-147.
21. Zaric GS, Barnett PG, Brandeau ML: HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health. 2000; 90: 1100-1111.
22. Yoast R, Williams MA, Deitchman SD, et al.: Report of the Council on Scientific Affairs: Methadone maintenance and needle-exchange programs to reduce the medical and public health consequences of drug abuse. J Addict Dis. 2001; 20: 15-40.
23. Stark K, Muller R, Bienzle U, et al.: Methadone maintenance treatment and HIV risk-taking behaviour among injecting drug users in Berlin. J Epidemiol Commun Health. 1996; 50: 534-537.
24. Mattick R, Ali R, White J: Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients. Addiction. 2002; 98: 441-452.
25. Metzger DS, Woody GE, McLellan AT, et al.: Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: An 18-month prospective follow-up. J Acquir Immune Defic Syndr. 1993; 6: 1049-1056.
26. Palepu A, Tyndall MW, Joy R, et al.: Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: The role of methadone maintenance therapy. Drug Alcohol Depend. 2006; 84: 188-194.
27. Lucas GM, Mullen BA, Weidle PJ, et al.: Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis. 2006; 42: 1628-1635.
28. Bruce RD, Altice FL, Gourevitch MN, et al.: Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: Implications and management for clinical practice. J Acquir Immune Defic Syndr. 2006; 41: 563-572.
29. Choopanya K, Des Jarlais DC, Vanichseni S, et al.: HIV risk reduction in a cohort of injecting drug users in Bangkok, Thailand. J Acquir Immune Defic Syndr. 2003; 33: 88-95.
30. Avants SK, Margolin A, Usubiaga MH, et al.: Targeting HIV-related outcomes with intravenous drug users maintained on methadone: A randomized clinical trial of a harm reduction group therapy. J Subst Abuse Treat. 2004; 26: 67-78.